Viking Therapeutics, Inc. 

VKTX Price

What is Viking Therapeutics (VKTX) tokenized stock?

Viking Therapeutics (VKTX) is a San Diego-based clinical-stage biopharmaceutical company developing therapies for obesity, metabolic, and endocrine disorders. The company has no approved products on the market, so the share's value depends on clinical trial outcomes. This page tracks tokenized versions of VKTX — the NASDAQ-listed equity wrapped into crypto instruments, including the RVKTX spot token and equity-referencing perpetual futures. Tokenized VKTX gives crypto traders on-chain price exposure to a biotech equity without a traditional brokerage account.

Is VKTX available as tokenized stock?

Yes. Per DropsTab data, tokenized VKTX trades as RVKTX — an rToken issued by Reality Protocol — against USDT, so spot exposure for tokenized VKTX runs through a single major CEX venue. Perpetual futures referencing the underlying NASDAQ share are tracked separately, giving traders synthetic exposure without the wrapped token itself.

How does tokenized VKTX track the NASDAQ share?

Tokenized VKTX packages price exposure to the NASDAQ-listed share into a crypto instrument — tokenized VKTX does not transfer ownership of an actual share. RVKTX is a wrapped-equity token: Reality Protocol issues the rToken, and the underlying equity sits with the wrapper's custody infrastructure. The wrapper price can trade at a premium or a discount to the NASDAQ share, which adds tracking risk on top of the biotech's clinical risk.

Where can traders buy VKTX tokenized stock — spot or perpetual futures?

Per DropsTab data, perpetual futures referencing VKTX trade on Binance Futures, Gate.io Futures, Bitunix Futures, and BVOX, while the RVKTX spot pair is listed on Bitget. Spot exposure is therefore narrower than futures exposure, and no DEX liquidity is tracked for tokenized VKTX. Most tracked VKTX exposure on crypto venues is synthetic via perpetuals rather than spot.

What is VK2735?

VK2735 is Viking Therapeutics' lead drug candidate — a dual GLP-1/GIP receptor agonist targeting obesity. VK2735 is being developed in two formulations: a weekly subcutaneous injection and an oral tablet. Late-stage testing includes the VANQUISH Phase 3 program for the injectable and the SUNRISE oral Phase 3 program. Clinical results from VK2735 trials are the primary driver of the underlying VKTX share value.

How does dilution of Viking Therapeutics shares affect tokenized VKTX?

Tokenized VKTX has no native crypto supply schedule, so the relevant supply figure is corporate: Viking Therapeutics reports about 127 million common shares outstanding per company filings. The share count is not fixed. New equity issuances and convertible-note conversions, disclosed in Viking Therapeutics' SEC filings, dilute the underlying share, and the dilution passes through to the price exposure of tokenized VKTX.

Why can tokenized VKTX trade at a premium or discount to the NASDAQ share?

The NASDAQ share trades only during exchange sessions, while crypto venues quote tokenized VKTX around the clock. Between sessions, the RVKTX price and the VKTX perpetual futures reflect crypto order flow rather than a live NASDAQ price. Thin spot liquidity on a single venue widens that gap, so the wrapper price can deviate from the NASDAQ share, upward or downward.

How is Viking Therapeutics funded as a company?

Viking Therapeutics funds itself through equity and convertible-note offerings. On September 24, 2026, the company priced an upsized offering of common stock and 2.00% convertible senior notes — upsized from an initially announced $200 million. Closing on September 28, 2026 delivered gross proceeds of about $575 million: 9,035,714 shares at $35.00 plus $258.75 million of notes. An earlier public offering raised about $550 million at $85.00 per share in February 2024. Proceeds fund late-stage VK2735 trials and launch readiness.

What are the risks of holding tokenized VKTX?

Tokenized VKTX carries stacked risk. The underlying share is event-driven: Viking Therapeutics has no approved products, and clinical outcomes for VK2735 determine the equity's value. The wrapper adds instrument risk — premiums or discounts to the NASDAQ share, wrapper-custody exposure, and thin spot liquidity given a single spot venue and no DEX presence. Repeated capital raises dilute the underlying share, and that dilution passes through to the price exposure of tokenized VKTX holders.